India commercially launches ROTAVAC vaccine
The rotavirus vaccine is the first new vaccine to have been entirely created in a developing country.
Clinical trials showed that ROTAVAC is safe and efficient in deceasing hospitalizations and preventing rotavirus diarrhea. The vaccine protects infants against several different strains of rotavirus. ROTAVAC’s effectiveness continues into the infant’s second year.
The affordable ROTAVAC vaccine requires three doses to be effective. The vaccine may prevent the 100,000 infant deaths from rotavirus diarrhea in India. It may also help prevent such deaths around the world.
“We have realized a dream by bringing out the first Made in India Molecule,” Bharat Biotech Chairman and Managing Director Krishna Ella said. “We have also maintained our pledge to offer ROTAVAC for $1 to governments in low-income countries. Our vaccine is affordable, safe and effective, besides being cross-protective against a variety of rotavirus strains.”
The vaccine is comparable to the current rotavirus vaccine that is licensed in countries with few resources.
"The ROTAVAC project is a beautiful example of the great power of team science,” Stanford University Associate Dean Harry Greenburg said. “The vaccine is a culmination of a very large and disparate group of people and organizations all working together for a common goal: to produce a safe, effective and affordable vaccine to prevent severe rotavirus associated diarrhea in Indian children.”